Neoplasia-related and treatment-induced lymphopenia: impact on the outcome of chemoradiotherapy in laryngeal cancer

References

• Anderson JL, Newman NB, Anderson C, Sherry AD, Yock AD, Osmundson EC. 2020. Mean cardiopulmonary dose and vertebral marrow dose differentially predict lineage-specific leukopenia kinetics during radiotherapy for esophageal cancer. Radiother Oncol. 152:169–176. doi:10.1016/j.radonc.2019.12.008
   PubMed Web of Science ®Google Scholar
• Bojaxhiu B, Templeton AJ, Elicin O, Shelan M, Zaugg K, Walser M, Giger R, Aebersold DM, Dal Pra A. 2018. Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation. Radiat Oncol. 13(1):216. doi:10.1186/s13014-018-1159-y
   PubMed Web of Science ®Google Scholar
• Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, Prevost JB, Modesto A, Lafond C, Tourani JM, et al. 2023. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol. 34(1):101–110. doi:10.1016/j.annonc.2022.10.006
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Jr, Psyrri A, Basté N, Neupane P, Bratland Å, et al. 2019. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 394(10212):1915–1928. doi:10.1016/S0140-6736(19)32591-7
   PubMed Web of Science ®Google Scholar
• Chandrasekara S, Davis S, Thomson P, Haydon A. 2018. High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy. Asia Pac J Clin Oncol. 14(5):e442–e447. doi:10.1111/ajco.12846
   PubMed Web of Science ®Google Scholar
• Cho Y, Kim JW, Yoon HI, Lee CG, Keum KC, Lee IJ. 2018. The Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Head and Neck Cancer Patients Treated with Radiotherapy. J Clin Med. 7(12):512. doi:10.3390/jcm7120512
   PubMed Web of Science ®Google Scholar
• Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, Harrington K, Chang PM, Lin JC, Razaq MA, et al. 2021. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 22(4):450–462. doi:10.1016/S1470-2045(20)30737-3
   PubMed Web of Science ®Google Scholar
• Ellsworth SG. 2018. Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors. Adv Radiat Oncol. 3(4):512–519. doi:10.1016/j.adro.2018.08.014
   PubMedGoogle Scholar
• Haddad CR, Guo L, Clarke S, Guminski A, Back M, Eade T. 2015. Neutrophil-to-lymphocyte ratio in head and neck cancer. J Med Imaging Radiat Oncol. 59(4):514–519. doi:10.1111/1754-9485.12305
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Ferris RL, Blumenschein G, Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, et al. 2017. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 18(8):1104–1115. doi:10.1016/S1470-2045(17)30421-7
   PubMed Web of Science ®Google Scholar
• Ho WJ, Yarchoan M, Hopkins A, Mehra R, Grossman S, Kang H. 2018. Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas. J Immunother Cancer. 6(1):84. doi:10.1186/s40425-018-0395-x
   PubMedGoogle Scholar
• Huang SH, O'Sullivan B. 2017. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Curr Treat Options Oncol. 18(7):40. doi:10.1007/s11864-017-0484-y
   PubMed Web of Science ®Google Scholar
• Jurin M, Suit HD. 1972. In vivo and in vitro studies of the influence of the immune status of C3Hf-Bu mice on the effectiveness of local irradiation of a methylcholanthrene-induced fibrosarcoma. Cancer Res. 32(10):2201–2211.
   PubMed Web of Science ®Google Scholar
• Kano S, Homma A, Hatakeyama H, Mizumachi T, Sakashita T, Kakizaki T, Fukuda S. 2017. Pretreatment lymphocyte-to-monocyte ratio as an independent prognostic factor for head and neck cancer. Head Neck. 39(2):247–253. doi:10.1002/hed.24576
   PubMed Web of Science ®Google Scholar
• Kim DY, Kim IS, Park SG, Kim H, Choi YJ, Seol YM. 2017. Prognostic value of posttreatment neutrophil-lymphocyte ratio in head and neck squamous cell carcinoma treated by chemoradiotherapy. Auris Nasus Larynx. 44(2):199–204. doi:10.1016/j.anl.2016.05.013
   PubMed Web of Science ®Google Scholar
• Koukourakis GV, Baksevanis CN, Zambatis H, Gritzapis A, Maltezos E, Simopoulos C, Koukourakis MI. 2009. Amifostine enhances recovery and expansion of peripheral FAS/CD95+ T- and NK-cell subpopulations during radiotherapy of patients with head-neck cancer. Int J Radiat Biol. 85(1):96–104. doi:10.1080/09553000802635070
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A. 2022. Tumor draining lymph nodes, immune response, and radiotherapy: Towards a revisal of therapeutic principles. Biochim Biophys Acta Rev Cancer. 1877(3):188704. doi:10.1016/j.bbcan.2022.188704
   PubMed Web of Science ®Google Scholar
• Koukourakis IM, Zygogianni A, Kouloulias V, Kyrgias G, Panteliadou M, Nanos C, Abatzoglou I, Koukourakis MI. 2021. Is Locally Advanced Head-Neck Cancer One More Candidate for Accelerated Hypofractionation? Anticancer Res. 41(1):467–475. doi:10.21873/anticanres.14797
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A. 2020. Tumor microenvironment, immune response and post-radiotherapy tumor clearance. Clin Transl Oncol. 22(12):2196–2205. doi:10.1007/s12094-020-02378-8
   PubMed Web of Science ®Google Scholar
• Lin YH, Chang KP, Lin YS, Chang TS. 2017. Pretreatment combination of platelet counts and neutrophil-lymphocyte ratio predicts survival of nasopharyngeal cancer patients receiving intensity-modulated radiotherapy. Onco Targets Ther. 10:2751–2760. doi:10.2147/OTT.S137000
   PubMed Web of Science ®Google Scholar
• Lin CH, Chou WC, Wu YY, Lin CY, Chang KP, Liao CT, Ho TY, Yeh CM, Liu CJ, Hung SP, et al. 2021. Prognostic significance of dynamic changes in lymphocyte-to-monocyte ratio in patients with head and neck cancer treated with radiotherapy: results from a large cohort study. Radiother Oncol. 154:76–86. doi:10.1016/j.radonc.2020.09.012
   PubMed Web of Science ®Google Scholar
• Ménétrier-Caux C, Ray-Coquard I, Blay JY, Caux C. 2019. Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines? J Immunother Cancer. 7(1):85. doi:10.1186/s40425-019-0549-5
   PubMed Web of Science ®Google Scholar
• Pike LRG, Bang A, Mahal BA, Taylor A, Krishnan M, Spektor A, Cagney DN, Aizer AA, Alexander BM, Rahma O, et al. 2019. The impact of radiation therapy on lymphocyte count and survival in metastatic cancer patients receiving PD-1 immune checkpoint inhibitors. Int J Radiat Oncol Biol Phys. 103(1):142–151. doi:10.1016/j.ijrobp.2018.09.010
   PubMed Web of Science ®Google Scholar
• Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall SC, et al. 2017. Systemic immunity is required for effective cancer immunotherapy. Cell. 168(3):487–502.e15. doi:10.1016/j.cell.2016.12.022
   PubMed Web of Science ®Google Scholar
• Suit HD, Kastelan A. 1970. Immunologic status of host and response of a methylcholanthrene-induced sarcoma to local x-irradiation. Cancer. 26(1):232–238. doi:10.1002/1097-0142(197007)26:1<232::aid-cncr2820260129>3.0.co;2-d
   PubMed Web of Science ®Google Scholar
• Venkatesulu BP, Mallick S, Lin SH, Krishnan S. 2018. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol. 123:42–51. doi:10.1016/j.critrevonc.2018.01.003
   PubMed Web of Science ®Google Scholar
• Wu YY, Chang KP, Lin CY, Pai PC, Wang HM, Hsu CL, Liao CT, Yen TC, Fang TJ, Huang SF, et al. 2018. Prognostic significance of combined pretreatment lymphocyte counts and body mass index in patients with head and neck cancer treated with radiation therapy. Cancer Med. 7(7):2808–2815. doi:10.1002/cam4.1489
   PubMed Web of Science ®Google Scholar
• Xu C, Jin JY, Zhang M, Liu A, Wang J, Mohan R, Kong FS, Lin SH. 2020. The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy. Radiother Oncol. 146:180–186. doi:10.1016/j.radonc.2020.02.015
   PubMed Web of Science ®Google Scholar
• Zhao T, Wang Y, Zhou D, Zhang W. 2023. Effects of pegylated recombinant human granulocyte colony-stimulating factor on lymphocytes and white blood cells of patients with malignant tumor. Open Life Sci. 18(1):20220590. doi:10.1515/biol-2022-0590
   PubMed Web of Science ®Google Scholar